Key Highlights

  • SIGA shares traded modestly lower with no single confirmed public catalyst explaining the specific session's move.
  • Full-year 2025 total revenues were about $94.6 million, down from $138.7 million in 2024, as stockpile deliveries normalized.
  • In January 2026, SIGA disclosed a $13 million international procurement order for oral TPOXX from an Asia Pacific nation under a multi-year contract.
  • The Balance Sheet remained solid, with cash and equivalents of roughly $155 million and stockholders' Equity near $199 million.

Few names capture the peculiar Economics of biodefense quite like SIGA Technologies Inc (NASDAQ: SIGA). The company sells a single flagship antiviral to governments stockpiling against smallpox and related orthopoxviruses, which makes its Revenue famously lumpy and its share price sensitive to procurement timing. After a softer trading session, attention has turned back to how SIGA converts a specialised Franchise into durable, repeatable sales, and whether 2026 order flow can steady a Business that saw revenue step down sharply last year.

Company and Latest Development

SIGA Technologies is an infectious-disease and biodefense company whose commercial product, TPOXX (tecovirimat), treats smallpox and is used in some markets against mpox and other orthopoxviruses. Its largest customer is the U.S. government, principally through the Strategic National Stockpile and the Biomedical Advanced Research and Development Authority (BARDA). SIGA also pursues international procurement and label expansions. In its most recent full-year results, the company reported deliveries of oral and intravenous TPOXX to the U.S. stockpile alongside international orders. It has continued to broaden TPOXX's global footprint, including a Japanese approval of the product for orthopoxvirus treatment disclosed in 2025, and additional BARDA contract funding tied to Manufacturing and pediatric development.

What Is Driving Attention Around SIGA?

SIGA is trading modestly lower, but no single confirmed public catalyst explains the move on that specific day. For a government-contract stock, day-to-day price action often reflects broader small-cap sentiment, procurement expectations and the absence of fresh order news rather than a discrete event. What is verifiable is the underlying rhythm of the business: 2025 revenue fell meaningfully from the prior year as stockpile deliveries normalised, and quarterly results can swing between profit and loss depending on shipment timing.

Key Numbers and Company Position

SIGA reported full-year 2025 total revenues of about $94.6 million, down from $138.7 million in 2024, with TPOXX product sales of roughly $88.0 million. Net Income was about $23.3 million ($0.32 diluted EPS), lower than 2024's $59.2 million. The fourth quarter was seasonally light, with product sales near $2.2 million and a net loss of about $5.4 million. The balance sheet remained solid, with cash and equivalents of roughly $155 million and stockholders' equity near $199 million. In January 2026, SIGA disclosed a $13 million international procurement order for oral TPOXX from an Asia Pacific nation under a multi-year contract, and it added funding to its BARDA 19C contract during 2025.

What Could Come Next?

Upcoming catalysts are tied to contracts and regulation. Investors may watch for additional U.S. stockpile orders and BARDA task-order funding, new or expanded international procurement, and progress on label and geographic expansion for TPOXX. Regulatory developments also matter: European authorities were expected to adjust TPOXX's orthopoxvirus labelling around early 2026, maintaining smallpox and cowpox indications.

Risks to Watch

SIGA's central risk is customer concentration: a large share of revenue depends on U.S. government purchasing decisions, which can shift with budgets, stockpile levels and policy priorities. Order timing produces uneven quarterly results and can pressure the stock. Regulatory changes to TPOXX indications in key markets, competition in antivirals, and the difficulty of diversifying a one-product portfolio add further uncertainty.

Smoothing Lumpy Procurement Revenue Is SIGA's Central Challenge

SIGA Technologies enters late 2026 as a profitable but concentrated biodefense specialist whose fortunes hinge on TPOXX procurement. The recent share weakness lacks a clearly identifiable catalyst, but the strategic picture is clear: after a step-down in 2025 revenue, new international orders and continued BARDA funding will shape sentiment. Investors may be watching order flow, regulatory labelling, and any move toward Diversification as the signals that determine whether SIGA can smooth its inherently lumpy sales.